Create Medicines secured $122 million in a Series B to fund therapies that express CARs in patients’ cells using mRNA delivered via liquid nanoparticles. The company expects the cash to last through 2028 and said it will support multiple clinical programs. Create Medicines’ stated focus includes CARs targeting TROP2, GPC3, HER2, and a combined HER2×TROP2 program, with plans to extend the platform to B-cell depletion in autoimmune diseases and move toward clinic entry in 2026. The financing underscores investor appetite for “in-body” gene expression approaches aimed at simplifying cell therapy manufacturing and scaling clinical deployment.